Unibest

Pharmaceutical intermediates

Luseogliflozin Intermediates

2 pharmaceutical intermediates for Luseogliflozin. Indication: Diabetes Mellitus, Type 2.

提交项目All intermediates

About Luseogliflozin

Originator
Taiho Pharmaceutical Co., Ltd.
Indication
Diabetes Mellitus, Type 2
Approved Date
03/24/2014

Available intermediates

2 intermediates currently listed for Luseogliflozin. Request specifications, documentation or a quotation for any item below.

Luseogliflozin intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-(4-ethoxybenzyl)-5-iodo-4-methoxy-2-methylbenzene1459754-49-4//
1-Bromo-5-(4-ethoxyphenylmethyl)-2-methoxy-4-methylbenzene898538-39-1//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Luseogliflozin?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →